Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 2:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–598 of 598 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: EconoPred Plus Clear all
Completed Phase 3 Interventional Results available

A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

NCT05232825
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions
Ocrelizumab IV, Ocrelizumab SC, Methylprednisolone IV, Diphenhydramine IV, Dexamethasone given orally, Desloratadine given orally
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Maitland, Florida • Tampa, Florida • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 27, 2026, 2:05 AM EDT
Terminated Phase 2 Interventional Results available

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

NCT04918147
View directory record Official record
Conditions
IgG4 Related Disease, IgG4-RD
Interventions
elotuzumab, placebo for elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine, prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 27, 2026, 2:05 AM EDT
Recruiting Phase 1Phase 2 Interventional

Stem Cell Transplantation in Crohn's Disease

NCT04224558
View directory record Official record
Conditions
Crohn Disease
Interventions
Mesna, Cyclophosphamide, Filgrastim, Apheresis catheter placement, Leukapheresis, Fludarabine, Methylprednisolone, Diphenhydramine, Acetaminophen, anti-thymocyte globulin (rabbit), lymphocyte immune globulin, Peripheral Blood Stem Cell Infusion, Cytoxan
Drug · Procedure · Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
13 Years to 28 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 27, 2026, 2:05 AM EDT
Enrolling by invitation Phase 3 Interventional

Reduce Opiate Exposure With ACL Surgery

NCT06561035
View directory record Official record
Conditions
Anterior Cruciate Ligament Injuries
Interventions
Opiate Sparing, Opiate Based
Drug
Lead sponsor
Campbell Clinic
Other
Eligibility
14 Years to 85 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Skokie, Illinois • Cincinnati, Ohio • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 27, 2026, 2:05 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00557193
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia
Interventions
Asparaginase, Biospecimen Collection, Bone Marrow Biopsy, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Echocardiography, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Lestaurtinib, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Pegaspargase, Pharmacological Study, Prednisone, Therapeutic Hydrocortisone, Vincristine Sulfate
Drug · Procedure · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 1 Year
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
157
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 120 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Oct 27, 2026, 2:05 AM EDT
Completed Phase 4 Interventional Results available

Steroid Free Immunosuppression in Liver Transplantation

NCT00296244
View directory record Official record
Conditions
Liver Cirrhosis, Liver Transplant Disorder
Interventions
Steroids, Basiliximab, Tacrolimus, Enteric-coated Mycophenolic acid (EC-MPA)
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 72 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Oct 27, 2026, 2:05 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification

NCT01193504
View directory record Official record
Conditions
Pseudophakia, Cataract Surgery
Interventions
Pred Forte, Lotemax
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
3
States / cities
Laguna Hills, California • Miami, Florida • Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 27, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT01718353
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
DOCETAXEL (XRP6976), CABAZITAXEL (XRP6258), Prednisone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Indianapolis, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 27, 2026, 2:05 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)

NCT02229422
View directory record Official record
Conditions
CLL
Interventions
GA101/HDMP
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 27, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

NCT02550652
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Mycophenolate Mofetil/Mycophenolic Acid, Obinutuzumab, Placebo, Methylprednisolone, Prednisone
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
7
States / cities
La Jolla, California • Palo Alto, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 27, 2026, 2:05 AM EDT
Completed Phase 3 Interventional

A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain

NCT04504812
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Duloxetine, Intra-Articular Injection, Nerve Procedure with long acting blocks, Nerve Procedure with nerve ablation, Pain Coping Skills Training, Best Practices
Drug · Combination Product · Procedure + 2 more
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1,937 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
24
States / cities
Sacramento, California • San Diego, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 27, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer

NCT00446030
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Docetaxel, Doxorubicin, Carboplatin, Cyclophosphamide, Trastuzumab, Bevacizumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 26, 2012 · Synced Oct 27, 2026, 2:05 AM EDT
Completed Phase 2Phase 3 Interventional Results available

MIS-C Comparative Effectiveness Study

NCT04898231
View directory record Official record
Conditions
Multisystem Inflammatory Syndrome-Children
Interventions
Infliximab, Anakinra, Methylprednisolone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Up to 20 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Diego, California • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 27, 2026, 2:05 AM EDT
Recruiting Phase 3 Interventional

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

NCT07365995
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
BNT324, Docetaxel, Prednisone/prednisolone
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older · Male only
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
21
States / cities
Santa Barbara, California • Aurora, Colorado • Fort Myers, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 27, 2026, 2:05 AM EDT
Not listed Not applicable Interventional

Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia

NCT00017654
View directory record Official record
Conditions
Graft Versus Host Disease, Aplastic Anemia
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, methylprednisolone, Allogeneic Bone Marrow Transplantation
Drug · Procedure
Lead sponsor
Northwestern Memorial Hospital
Other
Eligibility
15 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 2:05 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06356571
View directory record Official record
Conditions
Plasma Cell Myeloma Refractory
Interventions
Isatuximab SC-OBDS, Montelukast, Dexamethasone, Acetaminophen, Diphenhydramine, Methylprednisolone, Carfilzomib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Los Angeles, California • West Hollywood, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 27, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

NCT00474383
View directory record Official record
Conditions
Prostate Neoplasms
Interventions
Abiraterone acetate, Glucocorticoid
Drug
Lead sponsor
Cougar Biotechnology, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 27, 2026, 2:05 AM EDT
Completed Phase 2 Interventional

Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome

NCT02462252
View directory record Official record
Conditions
Aplastic Anemia, Hypoplastic Myelodysplastic Syndrome
Interventions
BL-8040, horse anti-thymocyte globulin (hATG), Methylprednisolone, Cyclosporine
Drug
Lead sponsor
BioLineRx, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 27, 2026, 2:05 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

NCT04221477
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Obinutuzumab, MMF, Prednisone, Placebo, Methylprednisolone, Acetaminophen, Diphenhydramine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • Fontana, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 27, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies

NCT01181258
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Interventions
Rituximab, Interleukin-2, Natural killer cells, Cyclophosphamide, Methylprednisolone, Fludarabine
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 27, 2026, 2:05 AM EDT
Completed Not applicable Interventional Results available

Oral Paricalcitol in Kidney Transplant Recipients

NCT00587158
View directory record Official record
Conditions
Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary
Interventions
Paricalcitol, Corticosteroid Avoidance Immune Suppression Protocol
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Oct 27, 2026, 2:05 AM EDT
Completed Phase 3 Interventional Results available

Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer

NCT00519285
View directory record Official record
Conditions
Prostatic Neoplasms, Neoplasm Metastasis
Interventions
Aflibercept, Placebo (for aflibercept), Docetaxel, Prednisone or Prednisolone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 22, 2016 · Synced Oct 27, 2026, 2:05 AM EDT